New developments in HCV therapy

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 1, 2012, Pages 48-51

  Kronenberger, B ^a   Zeuzem, S ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

boceprevir; direct antiviral agents against hepatitis C; NS3 4A protease inhibitors; NS5B polymerase inhibitors; telaprevir

Indexed keywords

ACH 2684; ALPHA INTERFERON; ANTIVIRUS AGENT; ASUNAPREVIR; BI 201335; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; GS 9256; MERICITABINE; MK 5172; NS3 PROTEASE INHIBITOR; NS5A PROTEIN INHIBITOR; NS5B POLYMERASE INHIBITOR; NUC POLYMERASE INHIBITOR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PPI 461; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84855691892     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01526.x     Document Type: Article

References (23)

1. Jacobson M, McHutchison J, Dusheiko G, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study. AASLD 2010; Abstract #211.
2. Kieffer T, Bartels D, Sullivan J, et al. Clinical virology results from telaprevir phase 3 study ADVANCE. AASLD 2010; LB-11.
3. Sherman K, Flamm S, Afdhal N, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. AASLD 2010; LB-2.
4. Telaprevir phase 3 trial fact sheet. Available at:; 2010 (accessed 31 May 2010).
5. Bronowicki J, McCone J, Bacon B, et al. Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-wk fixed-duration regimen with BOC + P/R in SPRINT-2. AASLD 2010; LB15.
6. Poordad F, McCone J, Bacon B, et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results. AASLD 2010; #LB4.
7. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin. AASLD 2010; #216.
8. Foster GR, Hezode C, Bronowicki JP, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2A and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: final results of study C209. J Hepatol 2010; 52: S27.
9. Benhamou Y, Moussalli J, Ratziu V, et al. Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 4 hepatitis-C patients: final results of study C210. AASLD 2010; #828.
10. Sarrazin C, Zeuzem S,. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138 (2): 447-462.
11. Huang M, Podos S, Patel D, et al. ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. AASLD 2010; #1859.
12. Brainard DM, Petry A, Van Dyck K, et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. AASLD 2010; #807.
13. Brown N, Vig P, Ruby E, et al. Safety and pharmacokinetics of PPI-461, a potent new hepatitis C virus NS5A inhibitor with pan-genotype activity. AASLD 2010; LB-12.
14. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
15. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
16. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
17. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1): 120-129.
18. Muir A, Lawitz E, Rodriguez-Torres M, et al. IL28B polymorphism and kinetics of antiviral activity for ANA598 in combination with pegylated interferon alfa2-a plus ribavirin in treatment naive genotype 1 chronic HCV patients. AASLD 2010; #1852.
19. Thompson A, Muir A, Sulkowski M, et al. Hepatitis C trials that combine investigational agents with pegylated interferon alfa should be stratified by IL28B genotype. AASLD 2010; #810.
20. Gane E, Roberts S, Stedman C, et al. Early on treatment responses during pegylated interferon plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1). J Hepatol 2010; 52: 291.
21. Zeuzem S, Asselah T, Angus PW, et al. Strong antiviral activity and safety of IFN sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. AASLD 2010; LB-7.
22. Mo H, Ku KS, Yang H, et al. Enhanced in vitro antiviral activity by combining GS-9256, a novel protease inhibitor, with GS-9190, a non-nucleoside NS5B inhibitor. AASLD 2010; #1867.
23. Lok AS, Gardiner DF, Lawitz E, et al. Combination therapy with BMS-790052 and BMS-650032 alone or with Peginterferon/ribavirin results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. AASLD 2010; LB-8.